nodes	percent_of_prediction	percent_of_DWPC	metapath
Amiloride—SLC22A4—larynx—thyroid cancer	0.0317	0.0788	CbGeAlD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.0292	0.106	CbGpPWpGaD
Amiloride—Blood potassium increased—Vandetanib—thyroid cancer	0.0262	0.0815	CcSEcCtD
Amiloride—PLAU—neck—thyroid cancer	0.024	0.0595	CbGeAlD
Amiloride—SCNN1G—saliva-secreting gland—thyroid cancer	0.021	0.0521	CbGeAlD
Amiloride—ASIC1—saliva-secreting gland—thyroid cancer	0.0206	0.0511	CbGeAlD
Amiloride—SLC9A1—saliva-secreting gland—thyroid cancer	0.0197	0.049	CbGeAlD
Amiloride—SCNN1B—saliva-secreting gland—thyroid cancer	0.0177	0.044	CbGeAlD
Amiloride—ASIC2—head—thyroid cancer	0.0176	0.0438	CbGeAlD
Amiloride—SCNN1A—saliva-secreting gland—thyroid cancer	0.0164	0.0407	CbGeAlD
Amiloride—PLAU—trachea—thyroid cancer	0.0144	0.0358	CbGeAlD
Amiloride—SCNN1B—trachea—thyroid cancer	0.0137	0.034	CbGeAlD
Amiloride—SCNN1G—thyroid gland—thyroid cancer	0.0128	0.0318	CbGeAlD
Amiloride—SCNN1A—trachea—thyroid cancer	0.0126	0.0314	CbGeAlD
Amiloride—SLC9A1—thyroid gland—thyroid cancer	0.012	0.0299	CbGeAlD
Amiloride—PLAU—thyroid gland—thyroid cancer	0.0114	0.0283	CbGeAlD
Amiloride—SCNN1D—head—thyroid cancer	0.0114	0.0282	CbGeAlD
Amiloride—ASIC1—head—thyroid cancer	0.0112	0.0277	CbGeAlD
Amiloride—SLC9A1—Defective B3GAT3 causes JDSSDHD—CHST14—thyroid cancer	0.011	0.0398	CbGpPWpGaD
Amiloride—SCNN1B—thyroid gland—thyroid cancer	0.0108	0.0269	CbGeAlD
Amiloride—SLC9A1—head—thyroid cancer	0.0107	0.0265	CbGeAlD
Amiloride—PLAU—head—thyroid cancer	0.0101	0.0251	CbGeAlD
Amiloride—SCNN1A—thyroid gland—thyroid cancer	0.01	0.0248	CbGeAlD
Amiloride—SCNN1B—head—thyroid cancer	0.0096	0.0238	CbGeAlD
Amiloride—SCNN1A—head—thyroid cancer	0.00887	0.022	CbGeAlD
Amiloride—PLAU—Beta1 integrin cell surface interactions—LAMA2—thyroid cancer	0.00885	0.0321	CbGpPWpGaD
Amiloride—SLC22A4—neck—thyroid cancer	0.00841	0.0209	CbGeAlD
Amiloride—SCNN1D—lymph node—thyroid cancer	0.00796	0.0197	CbGeAlD
Amiloride—ASIC1—lymph node—thyroid cancer	0.00781	0.0194	CbGeAlD
Amiloride—AOC1—lymph node—thyroid cancer	0.00781	0.0194	CbGeAlD
Amiloride—SLC9A1—lymph node—thyroid cancer	0.00748	0.0186	CbGeAlD
Amiloride—PLAU—lymph node—thyroid cancer	0.00709	0.0176	CbGeAlD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—TCF7L1—thyroid cancer	0.00707	0.0257	CbGpPWpGaD
Amiloride—SCNN1B—lymph node—thyroid cancer	0.00672	0.0167	CbGeAlD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—TCF7L1—thyroid cancer	0.00671	0.0243	CbGpPWpGaD
Amiloride—PLAU—Endochondral Ossification—PTCH1—thyroid cancer	0.00639	0.0232	CbGpPWpGaD
Amiloride—SCNN1A—lymph node—thyroid cancer	0.00621	0.0154	CbGeAlD
Amiloride—SLC9A1—G Protein Signaling Pathways—PRKAR1A—thyroid cancer	0.00608	0.0221	CbGpPWpGaD
Amiloride—SLC9A1—Carbohydrate metabolism—CHST14—thyroid cancer	0.00588	0.0213	CbGpPWpGaD
Amiloride—Hyponatraemia—Vandetanib—thyroid cancer	0.00577	0.0179	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Vandetanib—thyroid cancer	0.00574	0.0179	CcSEcCtD
Amiloride—SLC22A4—trachea—thyroid cancer	0.00506	0.0126	CbGeAlD
Amiloride—Gynaecomastia—Sorafenib—thyroid cancer	0.00477	0.0148	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—CDK1—thyroid cancer	0.00474	0.0172	CbGpPWpGaD
Amiloride—Neutropenia—Vandetanib—thyroid cancer	0.00464	0.0144	CcSEcCtD
Amiloride—Dysuria—Vandetanib—thyroid cancer	0.00464	0.0144	CcSEcCtD
Amiloride—Pollakiuria—Vandetanib—thyroid cancer	0.00459	0.0143	CcSEcCtD
Amiloride—PLAU—E2F transcription factor network—CDK1—thyroid cancer	0.00458	0.0166	CbGpPWpGaD
Amiloride—SLC9A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—thyroid cancer	0.00455	0.0165	CbGpPWpGaD
Amiloride—Hepatic function abnormal—Sorafenib—thyroid cancer	0.00443	0.0138	CcSEcCtD
Amiloride—Depression—Vandetanib—thyroid cancer	0.00441	0.0137	CcSEcCtD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—PTGS2—thyroid cancer	0.00422	0.0153	CbGpPWpGaD
Amiloride—Bradycardia—Vandetanib—thyroid cancer	0.00404	0.0126	CcSEcCtD
Amiloride—SLC22A4—thyroid gland—thyroid cancer	0.004	0.00994	CbGeAlD
Amiloride—Haemoglobin—Vandetanib—thyroid cancer	0.00399	0.0124	CcSEcCtD
Amiloride—Haemorrhage—Vandetanib—thyroid cancer	0.00397	0.0124	CcSEcCtD
Amiloride—Hyponatraemia—Sorafenib—thyroid cancer	0.00389	0.0121	CcSEcCtD
Amiloride—Pain in extremity—Sorafenib—thyroid cancer	0.00387	0.012	CcSEcCtD
Amiloride—Visual impairment—Vandetanib—thyroid cancer	0.00383	0.0119	CcSEcCtD
Amiloride—Alopecia—Vandetanib—thyroid cancer	0.00351	0.0109	CcSEcCtD
Amiloride—SLC22A1—head—thyroid cancer	0.00338	0.0084	CbGeAlD
Amiloride—Muscle spasms—Vandetanib—thyroid cancer	0.00333	0.0103	CcSEcCtD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCND1—thyroid cancer	0.00329	0.0119	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—HIF1A—thyroid cancer	0.00327	0.0119	CbGpPWpGaD
Amiloride—Tremor—Vandetanib—thyroid cancer	0.00324	0.0101	CcSEcCtD
Amiloride—Neutropenia—Sorafenib—thyroid cancer	0.00313	0.00974	CcSEcCtD
Amiloride—Erectile dysfunction—Sorafenib—thyroid cancer	0.00308	0.00959	CcSEcCtD
Amiloride—Cough—Vandetanib—thyroid cancer	0.00302	0.00938	CcSEcCtD
Amiloride—SLC9A1—RhoA signaling pathway—PTEN—thyroid cancer	0.00301	0.0109	CbGpPWpGaD
Amiloride—Chest pain—Vandetanib—thyroid cancer	0.00294	0.00916	CcSEcCtD
Amiloride—Arthralgia—Vandetanib—thyroid cancer	0.00294	0.00916	CcSEcCtD
Amiloride—Jaundice—Sorafenib—thyroid cancer	0.00291	0.00905	CcSEcCtD
Amiloride—ASIC2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00276	0.01	CbGpPWpGaD
Amiloride—ASIC2—Transmembrane transport of small molecules—CP—thyroid cancer	0.00276	0.01	CbGpPWpGaD
Amiloride—SLC22A4—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00273	0.00992	CbGpPWpGaD
Amiloride—SLC9A1—Carbohydrate metabolism—TPR—thyroid cancer	0.00272	0.00988	CbGpPWpGaD
Amiloride—ASIC2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00272	0.00986	CbGpPWpGaD
Amiloride—SLC9A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00271	0.00985	CbGpPWpGaD
Amiloride—SLC9A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00271	0.00985	CbGpPWpGaD
Amiloride—Haemoglobin—Sorafenib—thyroid cancer	0.00269	0.00838	CcSEcCtD
Amiloride—Haemorrhage—Sorafenib—thyroid cancer	0.00268	0.00833	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00257	0.008	CcSEcCtD
Amiloride—Insomnia—Vandetanib—thyroid cancer	0.00255	0.00794	CcSEcCtD
Amiloride—Paraesthesia—Vandetanib—thyroid cancer	0.00253	0.00788	CcSEcCtD
Amiloride—Dyspnoea—Vandetanib—thyroid cancer	0.00252	0.00782	CcSEcCtD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.00251	0.00911	CbGpPWpGaD
Amiloride—Tinnitus—Sorafenib—thyroid cancer	0.0025	0.00777	CcSEcCtD
Amiloride—SLC22A4—lymph node—thyroid cancer	0.00249	0.00618	CbGeAlD
Amiloride—Dyspepsia—Vandetanib—thyroid cancer	0.00248	0.00773	CcSEcCtD
Amiloride—Decreased appetite—Vandetanib—thyroid cancer	0.00245	0.00763	CcSEcCtD
Amiloride—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00244	0.00758	CcSEcCtD
Amiloride—Fatigue—Vandetanib—thyroid cancer	0.00243	0.00757	CcSEcCtD
Amiloride—Pain—Vandetanib—thyroid cancer	0.00241	0.00751	CcSEcCtD
Amiloride—Constipation—Vandetanib—thyroid cancer	0.00241	0.00751	CcSEcCtD
Amiloride—Alopecia—Sorafenib—thyroid cancer	0.00237	0.00736	CcSEcCtD
Amiloride—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00231	0.00718	CcSEcCtD
Amiloride—PLAU—ATF-2 transcription factor network—CCND1—thyroid cancer	0.00226	0.00822	CbGpPWpGaD
Amiloride—Muscle spasms—Sorafenib—thyroid cancer	0.00224	0.00697	CcSEcCtD
Amiloride—Abdominal pain—Vandetanib—thyroid cancer	0.00223	0.00694	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—BRAF—thyroid cancer	0.00217	0.00787	CbGpPWpGaD
Amiloride—Hyperuricaemia—Epirubicin—thyroid cancer	0.00213	0.00661	CcSEcCtD
Amiloride—SCNN1A—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00209	0.00759	CbGpPWpGaD
Amiloride—SCNN1B—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00209	0.00759	CbGpPWpGaD
Amiloride—SCNN1D—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00209	0.00759	CbGpPWpGaD
Amiloride—SCNN1G—Transmembrane transport of small molecules—CP—thyroid cancer	0.00209	0.00759	CbGpPWpGaD
Amiloride—SCNN1A—Transmembrane transport of small molecules—CP—thyroid cancer	0.00209	0.00759	CbGpPWpGaD
Amiloride—ASIC1—Transmembrane transport of small molecules—CP—thyroid cancer	0.00209	0.00759	CbGpPWpGaD
Amiloride—SCNN1B—Transmembrane transport of small molecules—CP—thyroid cancer	0.00209	0.00759	CbGpPWpGaD
Amiloride—SCNN1D—Transmembrane transport of small molecules—CP—thyroid cancer	0.00209	0.00759	CbGpPWpGaD
Amiloride—SCNN1G—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00209	0.00759	CbGpPWpGaD
Amiloride—ASIC1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00209	0.00759	CbGpPWpGaD
Amiloride—ASIC2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00207	0.0075	CbGpPWpGaD
Amiloride—SCNN1G—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00206	0.00747	CbGpPWpGaD
Amiloride—SCNN1D—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00206	0.00747	CbGpPWpGaD
Amiloride—SCNN1B—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00206	0.00747	CbGpPWpGaD
Amiloride—ASIC1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00206	0.00747	CbGpPWpGaD
Amiloride—SCNN1A—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00206	0.00747	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway—CCND1—thyroid cancer	0.00205	0.00742	CbGpPWpGaD
Amiloride—Cough—Sorafenib—thyroid cancer	0.00204	0.00633	CcSEcCtD
Amiloride—SLC9A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00203	0.00738	CbGpPWpGaD
Amiloride—Asthenia—Vandetanib—thyroid cancer	0.00203	0.0063	CcSEcCtD
Amiloride—Blood uric acid increased—Epirubicin—thyroid cancer	0.00201	0.00625	CcSEcCtD
Amiloride—Pruritus—Vandetanib—thyroid cancer	0.002	0.00621	CcSEcCtD
Amiloride—Neck pain—Epirubicin—thyroid cancer	0.002	0.00621	CcSEcCtD
Amiloride—Arthralgia—Sorafenib—thyroid cancer	0.00199	0.00618	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—CCND1—thyroid cancer	0.00197	0.00717	CbGpPWpGaD
Amiloride—Hepatocellular injury—Epirubicin—thyroid cancer	0.00197	0.00613	CcSEcCtD
Amiloride—Hyperuricaemia—Doxorubicin—thyroid cancer	0.00197	0.00612	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—BRAF—thyroid cancer	0.00196	0.0071	CbGpPWpGaD
Amiloride—Hyperkalaemia—Epirubicin—thyroid cancer	0.00194	0.00603	CcSEcCtD
Amiloride—Diarrhoea—Vandetanib—thyroid cancer	0.00193	0.006	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—PTEN—thyroid cancer	0.00191	0.00692	CbGpPWpGaD
Amiloride—Shock—Sorafenib—thyroid cancer	0.00187	0.00582	CcSEcCtD
Amiloride—Dizziness—Vandetanib—thyroid cancer	0.00187	0.0058	CcSEcCtD
Amiloride—Blood uric acid increased—Doxorubicin—thyroid cancer	0.00186	0.00578	CcSEcCtD
Amiloride—Aplastic anaemia—Epirubicin—thyroid cancer	0.00185	0.00576	CcSEcCtD
Amiloride—Neck pain—Doxorubicin—thyroid cancer	0.00185	0.00574	CcSEcCtD
Amiloride—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00183	0.00567	CcSEcCtD
Amiloride—Anorexia—Sorafenib—thyroid cancer	0.00181	0.00564	CcSEcCtD
Amiloride—Coma—Epirubicin—thyroid cancer	0.0018	0.0056	CcSEcCtD
Amiloride—Vomiting—Vandetanib—thyroid cancer	0.00179	0.00558	CcSEcCtD
Amiloride—Hyperkalaemia—Doxorubicin—thyroid cancer	0.00179	0.00558	CcSEcCtD
Amiloride—Rash—Vandetanib—thyroid cancer	0.00178	0.00553	CcSEcCtD
Amiloride—Dermatitis—Vandetanib—thyroid cancer	0.00178	0.00553	CcSEcCtD
Amiloride—SLC9A1—Disease—TRIM24—thyroid cancer	0.00177	0.00643	CbGpPWpGaD
Amiloride—Headache—Vandetanib—thyroid cancer	0.00177	0.0055	CcSEcCtD
Amiloride—SLC9A1—Metabolism—MINPP1—thyroid cancer	0.00175	0.00634	CbGpPWpGaD
Amiloride—ASIC2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00174	0.0063	CbGpPWpGaD
Amiloride—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00173	0.00539	CcSEcCtD
Amiloride—Aplastic anaemia—Doxorubicin—thyroid cancer	0.00171	0.00533	CcSEcCtD
Amiloride—Dyspnoea—Sorafenib—thyroid cancer	0.0017	0.00528	CcSEcCtD
Amiloride—Nausea—Vandetanib—thyroid cancer	0.00168	0.00521	CcSEcCtD
Amiloride—Dyspepsia—Sorafenib—thyroid cancer	0.00168	0.00521	CcSEcCtD
Amiloride—Coma—Doxorubicin—thyroid cancer	0.00167	0.00519	CcSEcCtD
Amiloride—SLC9A1—Disease—CHST14—thyroid cancer	0.00167	0.00605	CbGpPWpGaD
Amiloride—Decreased appetite—Sorafenib—thyroid cancer	0.00166	0.00515	CcSEcCtD
Amiloride—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00164	0.00511	CcSEcCtD
Amiloride—Fatigue—Sorafenib—thyroid cancer	0.00164	0.0051	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—BRAF—thyroid cancer	0.00164	0.00595	CbGpPWpGaD
Amiloride—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00164	0.00509	CcSEcCtD
Amiloride—Pain—Sorafenib—thyroid cancer	0.00163	0.00506	CcSEcCtD
Amiloride—Constipation—Sorafenib—thyroid cancer	0.00163	0.00506	CcSEcCtD
Amiloride—SLC9A1—Disease—TRIM33—thyroid cancer	0.00158	0.00573	CbGpPWpGaD
Amiloride—SCNN1A—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00157	0.00568	CbGpPWpGaD
Amiloride—SCNN1G—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00157	0.00568	CbGpPWpGaD
Amiloride—SCNN1D—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00157	0.00568	CbGpPWpGaD
Amiloride—ASIC1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00157	0.00568	CbGpPWpGaD
Amiloride—SCNN1B—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00157	0.00568	CbGpPWpGaD
Amiloride—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00156	0.00484	CcSEcCtD
Amiloride—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.00152	0.00471	CcSEcCtD
Amiloride—Abdominal pain—Sorafenib—thyroid cancer	0.00151	0.00468	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—NRAS—thyroid cancer	0.0015	0.00545	CbGpPWpGaD
Amiloride—SLC9A1—Endothelins—HRAS—thyroid cancer	0.0015	0.00545	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—NDUFA13—thyroid cancer	0.00148	0.00539	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—CCND1—thyroid cancer	0.00146	0.0053	CbGpPWpGaD
Amiloride—Hyponatraemia—Epirubicin—thyroid cancer	0.00144	0.00447	CcSEcCtD
Amiloride—Pain in extremity—Epirubicin—thyroid cancer	0.00143	0.00445	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.00143	0.00445	CcSEcCtD
Amiloride—PLAU—Hemostasis—PRKAR1A—thyroid cancer	0.00141	0.00513	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—CHST14—thyroid cancer	0.0014	0.00507	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CCND1—thyroid cancer	0.00139	0.00503	CbGpPWpGaD
Amiloride—SLC9A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.00138	0.00501	CbGpPWpGaD
Amiloride—SLC9A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00138	0.00501	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—PTEN—thyroid cancer	0.00138	0.005	CbGpPWpGaD
Amiloride—Asthenia—Sorafenib—thyroid cancer	0.00137	0.00425	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—NRAS—thyroid cancer	0.00136	0.00495	CbGpPWpGaD
Amiloride—SLC9A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00136	0.00493	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—AKT1—thyroid cancer	0.00135	0.00491	CbGpPWpGaD
Amiloride—Pruritus—Sorafenib—thyroid cancer	0.00135	0.00419	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—PTEN—thyroid cancer	0.00134	0.00485	CbGpPWpGaD
Amiloride—Hyponatraemia—Doxorubicin—thyroid cancer	0.00133	0.00414	CcSEcCtD
Amiloride—SLC9A1—Endothelins—AKT1—thyroid cancer	0.00132	0.00481	CbGpPWpGaD
Amiloride—Pain in extremity—Doxorubicin—thyroid cancer	0.00132	0.00412	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00132	0.00412	CcSEcCtD
Amiloride—SCNN1G—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00132	0.00478	CbGpPWpGaD
Amiloride—ASIC1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00132	0.00478	CbGpPWpGaD
Amiloride—SCNN1B—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00132	0.00478	CbGpPWpGaD
Amiloride—SCNN1D—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00132	0.00478	CbGpPWpGaD
Amiloride—SCNN1A—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00132	0.00478	CbGpPWpGaD
Amiloride—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00131	0.00407	CcSEcCtD
Amiloride—Diarrhoea—Sorafenib—thyroid cancer	0.0013	0.00405	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—TP53—thyroid cancer	0.0013	0.00472	CbGpPWpGaD
Amiloride—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00129	0.00469	CbGpPWpGaD
Amiloride—SLC9A1—G Protein Signaling Pathways—KRAS—thyroid cancer	0.00129	0.00469	CbGpPWpGaD
Amiloride—Muscular weakness—Epirubicin—thyroid cancer	0.00126	0.00393	CcSEcCtD
Amiloride—Dizziness—Sorafenib—thyroid cancer	0.00126	0.00392	CcSEcCtD
Amiloride—Abdominal distension—Epirubicin—thyroid cancer	0.00125	0.00387	CcSEcCtD
Amiloride—SLC22A4—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00124	0.00451	CbGpPWpGaD
Amiloride—SLC22A4—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00124	0.00451	CbGpPWpGaD
Amiloride—Vomiting—Sorafenib—thyroid cancer	0.00121	0.00376	CcSEcCtD
Amiloride—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00121	0.00376	CcSEcCtD
Amiloride—Angina pectoris—Epirubicin—thyroid cancer	0.00121	0.00375	CcSEcCtD
Amiloride—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00121	0.00437	CbGpPWpGaD
Amiloride—Rash—Sorafenib—thyroid cancer	0.0012	0.00373	CcSEcCtD
Amiloride—Dermatitis—Sorafenib—thyroid cancer	0.0012	0.00373	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—NRAS—thyroid cancer	0.00119	0.00433	CbGpPWpGaD
Amiloride—Headache—Sorafenib—thyroid cancer	0.00119	0.00371	CcSEcCtD
Amiloride—PLAU—Endochondral Ossification—AKT1—thyroid cancer	0.00118	0.00428	CbGpPWpGaD
Amiloride—SLC9A1—ErbB1 downstream signaling—KRAS—thyroid cancer	0.00117	0.00426	CbGpPWpGaD
Amiloride—Muscular weakness—Doxorubicin—thyroid cancer	0.00117	0.00363	CcSEcCtD
Amiloride—Neutropenia—Epirubicin—thyroid cancer	0.00116	0.0036	CcSEcCtD
Amiloride—Dysuria—Epirubicin—thyroid cancer	0.00116	0.0036	CcSEcCtD
Amiloride—Abdominal distension—Doxorubicin—thyroid cancer	0.00115	0.00358	CcSEcCtD
Amiloride—Pollakiuria—Epirubicin—thyroid cancer	0.00114	0.00355	CcSEcCtD
Amiloride—Nausea—Sorafenib—thyroid cancer	0.00113	0.00352	CcSEcCtD
Amiloride—SLC9A1—Metabolism—HPGD—thyroid cancer	0.00113	0.00408	CbGpPWpGaD
Amiloride—Angina pectoris—Doxorubicin—thyroid cancer	0.00112	0.00347	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—HRAS—thyroid cancer	0.0011	0.00399	CbGpPWpGaD
Amiloride—Jaundice—Epirubicin—thyroid cancer	0.00108	0.00334	CcSEcCtD
Amiloride—Dysuria—Doxorubicin—thyroid cancer	0.00107	0.00333	CcSEcCtD
Amiloride—Neutropenia—Doxorubicin—thyroid cancer	0.00107	0.00333	CcSEcCtD
Amiloride—Pollakiuria—Doxorubicin—thyroid cancer	0.00106	0.00329	CcSEcCtD
Amiloride—SLC9A1—Disease—TCF7L1—thyroid cancer	0.00105	0.00383	CbGpPWpGaD
Amiloride—SLC9A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00103	0.00375	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—NRAS—thyroid cancer	0.00103	0.00374	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—KRAS—thyroid cancer	0.00103	0.00373	CbGpPWpGaD
Amiloride—Bradycardia—Epirubicin—thyroid cancer	0.00101	0.00314	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—HRAS—thyroid cancer	0.000997	0.00362	CbGpPWpGaD
Amiloride—Haemoglobin—Epirubicin—thyroid cancer	0.000995	0.0031	CcSEcCtD
Amiloride—Jaundice—Doxorubicin—thyroid cancer	0.000995	0.00309	CcSEcCtD
Amiloride—Haemorrhage—Epirubicin—thyroid cancer	0.00099	0.00308	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—TP53—thyroid cancer	0.000963	0.00349	CbGpPWpGaD
Amiloride—Visual impairment—Epirubicin—thyroid cancer	0.000954	0.00297	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—TP53—thyroid cancer	0.00094	0.00341	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—IFNA2—thyroid cancer	0.000937	0.0034	CbGpPWpGaD
Amiloride—Bradycardia—Doxorubicin—thyroid cancer	0.000933	0.0029	CcSEcCtD
Amiloride—SLC22A4—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00093	0.00338	CbGpPWpGaD
Amiloride—Tinnitus—Epirubicin—thyroid cancer	0.000923	0.00287	CcSEcCtD
Amiloride—Haemoglobin—Doxorubicin—thyroid cancer	0.000921	0.00286	CcSEcCtD
Amiloride—Haemorrhage—Doxorubicin—thyroid cancer	0.000916	0.00285	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—TP53—thyroid cancer	0.000913	0.00331	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—HRAS—thyroid cancer	0.000899	0.00326	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—KRAS—thyroid cancer	0.000887	0.00322	CbGpPWpGaD
Amiloride—Visual impairment—Doxorubicin—thyroid cancer	0.000883	0.00275	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—AKT1—thyroid cancer	0.00088	0.0032	CbGpPWpGaD
Amiloride—Alopecia—Epirubicin—thyroid cancer	0.000875	0.00272	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—HRAS—thyroid cancer	0.000873	0.00317	CbGpPWpGaD
Amiloride—SLC9A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000868	0.00315	CbGpPWpGaD
Amiloride—Tinnitus—Doxorubicin—thyroid cancer	0.000854	0.00266	CcSEcCtD
Amiloride—Flatulence—Epirubicin—thyroid cancer	0.00085	0.00264	CcSEcCtD
Amiloride—Tension—Epirubicin—thyroid cancer	0.000846	0.00263	CcSEcCtD
Amiloride—Nervousness—Epirubicin—thyroid cancer	0.000837	0.0026	CcSEcCtD
Amiloride—Back pain—Epirubicin—thyroid cancer	0.000834	0.00259	CcSEcCtD
Amiloride—Muscle spasms—Epirubicin—thyroid cancer	0.000829	0.00258	CcSEcCtD
Amiloride—Alopecia—Doxorubicin—thyroid cancer	0.00081	0.00252	CcSEcCtD
Amiloride—Flatulence—Doxorubicin—thyroid cancer	0.000786	0.00244	CcSEcCtD
Amiloride—Tension—Doxorubicin—thyroid cancer	0.000783	0.00243	CcSEcCtD
Amiloride—Nervousness—Doxorubicin—thyroid cancer	0.000775	0.00241	CcSEcCtD
Amiloride—Vertigo—Epirubicin—thyroid cancer	0.000775	0.00241	CcSEcCtD
Amiloride—Back pain—Doxorubicin—thyroid cancer	0.000772	0.0024	CcSEcCtD
Amiloride—SLC9A1—Disease—TPR—thyroid cancer	0.000772	0.0028	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—AKT1—thyroid cancer	0.000771	0.0028	CbGpPWpGaD
Amiloride—Muscle spasms—Doxorubicin—thyroid cancer	0.000767	0.00238	CcSEcCtD
Amiloride—Palpitations—Epirubicin—thyroid cancer	0.000762	0.00237	CcSEcCtD
Amiloride—SLC9A1—Disease—PRKAR1A—thyroid cancer	0.000759	0.00275	CbGpPWpGaD
Amiloride—Cough—Epirubicin—thyroid cancer	0.000752	0.00234	CcSEcCtD
Amiloride—Arthralgia—Epirubicin—thyroid cancer	0.000734	0.00228	CcSEcCtD
Amiloride—Chest pain—Epirubicin—thyroid cancer	0.000734	0.00228	CcSEcCtD
Amiloride—SLC9A1—Disease—MEN1—thyroid cancer	0.000725	0.00263	CbGpPWpGaD
Amiloride—Vertigo—Doxorubicin—thyroid cancer	0.000717	0.00223	CcSEcCtD
Amiloride—Confusional state—Epirubicin—thyroid cancer	0.00071	0.00221	CcSEcCtD
Amiloride—Palpitations—Doxorubicin—thyroid cancer	0.000705	0.00219	CcSEcCtD
Amiloride—Cough—Doxorubicin—thyroid cancer	0.000696	0.00216	CcSEcCtD
Amiloride—Shock—Epirubicin—thyroid cancer	0.000692	0.00215	CcSEcCtD
Amiloride—Arthralgia—Doxorubicin—thyroid cancer	0.000679	0.00211	CcSEcCtD
Amiloride—Chest pain—Doxorubicin—thyroid cancer	0.000679	0.00211	CcSEcCtD
Amiloride—Anorexia—Epirubicin—thyroid cancer	0.000671	0.00209	CcSEcCtD
Amiloride—Confusional state—Doxorubicin—thyroid cancer	0.000656	0.00204	CcSEcCtD
Amiloride—SLC9A1—Metabolism—TPR—thyroid cancer	0.000646	0.00234	CbGpPWpGaD
Amiloride—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000641	0.00199	CcSEcCtD
Amiloride—Shock—Doxorubicin—thyroid cancer	0.000641	0.00199	CcSEcCtD
Amiloride—Insomnia—Epirubicin—thyroid cancer	0.000636	0.00198	CcSEcCtD
Amiloride—SLC9A1—Metabolism—PRKAR1A—thyroid cancer	0.000636	0.00231	CbGpPWpGaD
Amiloride—Paraesthesia—Epirubicin—thyroid cancer	0.000632	0.00196	CcSEcCtD
Amiloride—SLC22A4—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000631	0.00229	CbGpPWpGaD
Amiloride—SLC22A4—Transmembrane transport of small molecules—CP—thyroid cancer	0.000631	0.00229	CbGpPWpGaD
Amiloride—Dyspnoea—Epirubicin—thyroid cancer	0.000627	0.00195	CcSEcCtD
Amiloride—Somnolence—Epirubicin—thyroid cancer	0.000626	0.00195	CcSEcCtD
Amiloride—SLC22A4—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000621	0.00225	CbGpPWpGaD
Amiloride—Anorexia—Doxorubicin—thyroid cancer	0.000621	0.00193	CcSEcCtD
Amiloride—Dyspepsia—Epirubicin—thyroid cancer	0.000619	0.00193	CcSEcCtD
Amiloride—Decreased appetite—Epirubicin—thyroid cancer	0.000612	0.0019	CcSEcCtD
Amiloride—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000607	0.00189	CcSEcCtD
Amiloride—Fatigue—Epirubicin—thyroid cancer	0.000607	0.00189	CcSEcCtD
Amiloride—Pain—Epirubicin—thyroid cancer	0.000602	0.00187	CcSEcCtD
Amiloride—Constipation—Epirubicin—thyroid cancer	0.000602	0.00187	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000593	0.00184	CcSEcCtD
Amiloride—Insomnia—Doxorubicin—thyroid cancer	0.000589	0.00183	CcSEcCtD
Amiloride—SLC22A2—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000588	0.00213	CbGpPWpGaD
Amiloride—SLC22A2—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000588	0.00213	CbGpPWpGaD
Amiloride—Paraesthesia—Doxorubicin—thyroid cancer	0.000585	0.00182	CcSEcCtD
Amiloride—Dyspnoea—Doxorubicin—thyroid cancer	0.00058	0.0018	CcSEcCtD
Amiloride—Feeling abnormal—Epirubicin—thyroid cancer	0.00058	0.0018	CcSEcCtD
Amiloride—Somnolence—Doxorubicin—thyroid cancer	0.000579	0.0018	CcSEcCtD
Amiloride—SLC9A1—Disease—CALCA—thyroid cancer	0.000578	0.0021	CbGpPWpGaD
Amiloride—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000575	0.00179	CcSEcCtD
Amiloride—Dyspepsia—Doxorubicin—thyroid cancer	0.000573	0.00178	CcSEcCtD
Amiloride—Decreased appetite—Doxorubicin—thyroid cancer	0.000566	0.00176	CcSEcCtD
Amiloride—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000562	0.00175	CcSEcCtD
Amiloride—Fatigue—Doxorubicin—thyroid cancer	0.000561	0.00175	CcSEcCtD
Amiloride—Constipation—Doxorubicin—thyroid cancer	0.000557	0.00173	CcSEcCtD
Amiloride—Pain—Doxorubicin—thyroid cancer	0.000557	0.00173	CcSEcCtD
Amiloride—Abdominal pain—Epirubicin—thyroid cancer	0.000556	0.00173	CcSEcCtD
Amiloride—SLC22A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000548	0.00199	CbGpPWpGaD
Amiloride—SLC22A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000548	0.00199	CbGpPWpGaD
Amiloride—Feeling abnormal—Doxorubicin—thyroid cancer	0.000537	0.00167	CcSEcCtD
Amiloride—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000532	0.00166	CcSEcCtD
Amiloride—SLC9A1—Disease—CDK1—thyroid cancer	0.000523	0.0019	CbGpPWpGaD
Amiloride—Abdominal pain—Doxorubicin—thyroid cancer	0.000515	0.0016	CcSEcCtD
Amiloride—Asthenia—Epirubicin—thyroid cancer	0.000505	0.00157	CcSEcCtD
Amiloride—Pruritus—Epirubicin—thyroid cancer	0.000498	0.00155	CcSEcCtD
Amiloride—SLC9A1—Metabolism—SLC5A5—thyroid cancer	0.000484	0.00176	CbGpPWpGaD
Amiloride—Diarrhoea—Epirubicin—thyroid cancer	0.000481	0.0015	CcSEcCtD
Amiloride—SLC22A4—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000473	0.00172	CbGpPWpGaD
Amiloride—Asthenia—Doxorubicin—thyroid cancer	0.000467	0.00145	CcSEcCtD
Amiloride—Dizziness—Epirubicin—thyroid cancer	0.000465	0.00145	CcSEcCtD
Amiloride—Pruritus—Doxorubicin—thyroid cancer	0.000461	0.00143	CcSEcCtD
Amiloride—Vomiting—Epirubicin—thyroid cancer	0.000447	0.00139	CcSEcCtD
Amiloride—Diarrhoea—Doxorubicin—thyroid cancer	0.000445	0.00139	CcSEcCtD
Amiloride—Rash—Epirubicin—thyroid cancer	0.000444	0.00138	CcSEcCtD
Amiloride—Dermatitis—Epirubicin—thyroid cancer	0.000443	0.00138	CcSEcCtD
Amiloride—Headache—Epirubicin—thyroid cancer	0.000441	0.00137	CcSEcCtD
Amiloride—SLC22A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00044	0.0016	CbGpPWpGaD
Amiloride—Dizziness—Doxorubicin—thyroid cancer	0.000431	0.00134	CcSEcCtD
Amiloride—SLC9A1—Disease—NRG1—thyroid cancer	0.00042	0.00152	CbGpPWpGaD
Amiloride—Nausea—Epirubicin—thyroid cancer	0.000418	0.0013	CcSEcCtD
Amiloride—Vomiting—Doxorubicin—thyroid cancer	0.000414	0.00129	CcSEcCtD
Amiloride—Rash—Doxorubicin—thyroid cancer	0.000411	0.00128	CcSEcCtD
Amiloride—Dermatitis—Doxorubicin—thyroid cancer	0.00041	0.00128	CcSEcCtD
Amiloride—SLC22A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00041	0.00149	CbGpPWpGaD
Amiloride—Headache—Doxorubicin—thyroid cancer	0.000408	0.00127	CcSEcCtD
Amiloride—SLC9A1—Metabolism—RXRA—thyroid cancer	0.000406	0.00147	CbGpPWpGaD
Amiloride—SLC22A4—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000397	0.00144	CbGpPWpGaD
Amiloride—Nausea—Doxorubicin—thyroid cancer	0.000387	0.0012	CcSEcCtD
Amiloride—SLC22A2—Metabolism—MINPP1—thyroid cancer	0.000378	0.00137	CbGpPWpGaD
Amiloride—SLC9A1—Disease—TERT—thyroid cancer	0.000377	0.00137	CbGpPWpGaD
Amiloride—SLC9A1—Disease—HIF1A—thyroid cancer	0.00036	0.00131	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—MINPP1—thyroid cancer	0.000352	0.00128	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—NRAS—thyroid cancer	0.000349	0.00127	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—NDUFA13—thyroid cancer	0.000321	0.00117	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—CHST14—thyroid cancer	0.000302	0.0011	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—KRAS—thyroid cancer	0.000301	0.00109	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—NDUFA13—thyroid cancer	0.000299	0.00109	CbGpPWpGaD
Amiloride—SLC22A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000299	0.00108	CbGpPWpGaD
Amiloride—SLC22A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000299	0.00108	CbGpPWpGaD
Amiloride—SLC9A1—Disease—BRAF—thyroid cancer	0.000298	0.00108	CbGpPWpGaD
Amiloride—SLC22A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000294	0.00107	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—CHST14—thyroid cancer	0.000282	0.00102	CbGpPWpGaD
Amiloride—SLC22A2—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.00028	0.00102	CbGpPWpGaD
Amiloride—SLC22A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000278	0.00101	CbGpPWpGaD
Amiloride—SLC22A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000278	0.00101	CbGpPWpGaD
Amiloride—SLC22A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000274	0.000994	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—TP53—thyroid cancer	0.000267	0.00097	CbGpPWpGaD
Amiloride—SLC22A1—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000261	0.000948	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PPARG—thyroid cancer	0.000257	0.000931	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—HRAS—thyroid cancer	0.000256	0.000928	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—HPGD—thyroid cancer	0.000244	0.000884	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PTGS2—thyroid cancer	0.000241	0.000875	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—HPGD—thyroid cancer	0.000227	0.000824	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—AKT1—thyroid cancer	0.000226	0.000819	CbGpPWpGaD
Amiloride—SLC22A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000224	0.000811	CbGpPWpGaD
Amiloride—SLC22A2—Neuronal System—BRAF—thyroid cancer	0.000215	0.000779	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PTEN—thyroid cancer	0.00021	0.000763	CbGpPWpGaD
Amiloride—SLC22A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000208	0.000756	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PTGS2—thyroid cancer	0.000202	0.000733	CbGpPWpGaD
Amiloride—SLC22A1—Neuronal System—BRAF—thyroid cancer	0.0002	0.000727	CbGpPWpGaD
Amiloride—SLC22A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000188	0.000682	CbGpPWpGaD
Amiloride—SLC9A1—Disease—NRAS—thyroid cancer	0.000188	0.000681	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PTEN—thyroid cancer	0.000176	0.000639	CbGpPWpGaD
Amiloride—SLC22A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000175	0.000635	CbGpPWpGaD
Amiloride—SLC9A1—Disease—KRAS—thyroid cancer	0.000161	0.000586	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—TPR—thyroid cancer	0.00014	0.000508	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PRKAR1A—thyroid cancer	0.000138	0.000499	CbGpPWpGaD
Amiloride—SLC9A1—Disease—HRAS—thyroid cancer	0.000137	0.000498	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—TPR—thyroid cancer	0.00013	0.000473	CbGpPWpGaD
Amiloride—SLC22A2—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000129	0.000468	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PRKAR1A—thyroid cancer	0.000128	0.000465	CbGpPWpGaD
Amiloride—SLC9A1—Disease—AKT1—thyroid cancer	0.000121	0.00044	CbGpPWpGaD
Amiloride—SLC22A1—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.00012	0.000436	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—SLC5A5—thyroid cancer	0.000105	0.00038	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—AKT1—thyroid cancer	0.000101	0.000368	CbGpPWpGaD
Amiloride—SLC22A2—Neuronal System—HRAS—thyroid cancer	9.88e-05	0.000358	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—SLC5A5—thyroid cancer	9.76e-05	0.000354	CbGpPWpGaD
Amiloride—SLC22A1—Neuronal System—HRAS—thyroid cancer	9.2e-05	0.000334	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—RXRA—thyroid cancer	8.8e-05	0.000319	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—RXRA—thyroid cancer	8.2e-05	0.000298	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PPARG—thyroid cancer	5.55e-05	0.000202	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PPARG—thyroid cancer	5.18e-05	0.000188	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PTGS2—thyroid cancer	4.37e-05	0.000159	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PTGS2—thyroid cancer	4.07e-05	0.000148	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PTEN—thyroid cancer	3.81e-05	0.000138	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PTEN—thyroid cancer	3.55e-05	0.000129	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—AKT1—thyroid cancer	2.2e-05	7.97e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—AKT1—thyroid cancer	2.05e-05	7.43e-05	CbGpPWpGaD
